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Abstract We undertook this study to determine whether patients with late-onset hypogammaglobulinemia, who are at very high risk for gastric cancer, have a reduced secretion of gastrin after stimulation with food or bombe sin, a potent gastrin-releasing stimulus. We compared the plasma gastrin responses to bombesin and to a standard test meal in 18 patients with late-onset hypogammaglob ulinemia with those in patients with X-linked agamma globulinemia, early-onset hypogammaglobulinemia, or hy pogammaglobulinemia due to lymphoproliferative cancer, and in 30 normal control subjects. Thirteen of 18 patients with late-onset hypogammaglob ulinemia (72 percent) had an abnormally low gastrin response to bombesin, as compared with none of 21 patients with other forms of hypogammaglobulinemia H YPO G A M M A G LO B U LIN E M IA comprises a heterogeneous group of immunodeficiency dis orders.1,2 O f the congenital forms, X-linked agamma globulinemia has been studied the most thoroughly and is characterized by an absence of B lymphocytes in the bone marrow, peripheral blood, and lymphoid tissues. 3 In addition to an increased susceptibility to infec tion, patients with primary hypogammaglobulinemia often have abnormalities of the gastrointestinal tract, including malabsorption, lymphonodular small-intes tinal hyperplasia, pernicious anemia, and gastric cancer 5,12-23 These gastrointestinal disorders have been 1564 THE NEW ENGLAND JOURNAL OF MEDICINE June 16, 1988 reported mainly in patients with late-onset hypogammaglobulinemia,D 'l4'24'2 :> but recent studies indicate that patients with other types of hypogammaglobulin emia may also have such abnormalities.15?26 Patients with late-onset hypogammaglobulinemia have a 50fold increase in the incidence of stomach cancer.2' Patients with the intestinal type of gastric cancer have a reduced plasma gastrin response to the gastrinreleasing peptide bombesin. 28 We therefore studied plasma gastrin secretion during bombesin infusion in patients with various forms of hypogammaglobuline mia to determine whether such patients have abnor malities in gastrin secretion after stimulation and whether those abnormalities are speciiic to subgroups of patients with hypogammaglobulinemia. Since bom besin is not readily available, we also measured post prandial plasma gastrin levels to determine whether bombesin can be replaced by a meal as a stimulant of gastrin secretion.
M e t h o d s

Patients
T h e study was performed in a group o f 33 patients with primary hypogammaglobulinemia, consisting of 10 male patients with Xlinkcd hypogammaglobulinemia (mean age, 23 years; range, 14 to 35), 5 patients (4 male and 1 female patient) with early-onset hypo gammaglobulinemia (mean age, 22 years; range, 17 to 25), and 18 patients (13 men and 5 women) with late-onset hypogam m aglobu linemia (mean age, 42 years; range, 21 to 67). W e also studied six patients (five men and one woman; 40 to 70 years of age) with hypogammaglobulinemia due to lymphoproliferative can cer-two with chronic lymphocytic leukemia, one with non-Hodgkin's lym phoma, and three with multiple myeloma. Thirty normal subjects (24 men and 6 women; mean age, 43 years; range, 24 to 72) with neither immunodeficiency nor recurrent infection served as con-4 trols. Before treatment, all patients with hypogammaglobulinemia except one had markedly reduced serum gammaglobulin concentra tions (range, 0 to 4.5 g per liter). O ne patient with a gammaglobulin concentration o f 6.0 g per liter, a member of a family with X-linked agammaglobulinemia, had no IgA, IgM , Ig G 2, or IgG 4 , but had nearly normal concentrations of IgG l and Ig G 3 -a finding that has been reported elsewhere.29
Informed consent was obtained from all subjects, and the proto col was approved by the ethics committee of the University Hospi tal of Leiden.
Criteria
T h e criteria for the diagnosis o f X-linkcd agammaglobulinemia were the onset of clinical signs during the first two years of life, a family history compatible with an X-linked pattern of inheritance, and an absence of or profound decrease in B lymphocytes in the peripheral blood or bone marrow. In patients in whom clinical symptoms began before the age of two years but no evidence for X-linked inheritance was found, the diagnosis of early-onset hypo gam m aglobulinem ia was made. In these patients, B lymphocytes were either absent, scarce, or present in normal numbers. Patients were considered to have late-onset hypogammaglobulinemia if clinical manifestations began after the age of 10 years and B lym phocytes, but not plasma cells, were found in the bone marrow.
Bombesin-lnfusion and Food Stimulation of Gastrin Secretion
Patients were studied after they had fasted overnight. Plasma gastrin levels after stimulation with bombesin were measured in all subjects, whereas gastrin levels after stimulation with food were measured in all 10 patients with 
R e s u l t s
In the normal subjects, plasma concentrations of gastrin ranged from 10 to 40 pmol per liter. A reduced basal plasma concentration of gastrin after bombesin stimulation was observed in 6 of the 18 patients (33 percent) with late-onset hypogammaglobulinemia as compared with none of the 21 patients with the other forms of hypogammaglobulinemia (P<0.05). Both bombesin and food increased plasma gastrin levels in all groups of subjects studied ( Fig. 1 and 2) . A reduc tion in integrated plasma gastrin secretion in response to bombesin was observed in 13 of the 18 patients (72 percent) with late-onset hypogammaglobulinemia, as compared with none of the 21 patients with other forms of hypogammaglobulinemia (P<0.05; Fig. 1 ), whereas a reduced postprandial level of plasma gas trin secretion was found in 6 of the 14 (43 percent) and 1 of the 18 patients (6 percent) with late-onset and other forms of hypogammaglobulinemia, respec tively (P not significant; Fig. 2 ). The incremental plasma gastrin secretion in the patients with late-onset hypogammaglobulinemia was reduced in 13 of the 18 patients who received bombesin (72 percent) and in 4 of the 14 who were given food (29 percent), as compared with none of the 21 and 18 patients with other forms of hypogammaglobulinemia who received bombesin (P<0.05) and food (P not signifi cant), respectively.
The low levels of plasma gastrin secretion in the patients with late-onset hypogammaglobulinemia were not correlated with age (r = 0.19), sex, or dura tion of illness (r = 0.12).
D i s c u s s i o n
We found a reduced gastrin response to the infusion of bombesin or the ingestion of food in 33 and 22 percent, respectively, of patients with hypogamma globulinemia. Interestingly, these abnormalities were restricted to patients with late-onset hypogammaglob- Bombesin was given to 30 normal subjects, 18 patients with lateonset hypogammaglobulinemia, and 21 patients with other forms of hypogammaglobulinemia: 10 with X-linked agammaglobuline mia (crosses), 5 with early-onset hypogammaglobulinemia (solid circles), and 6 with secondary hypogammaglobulinemia (trian gles). pM-20min denotes picomoles per liter per 20 minutes.
ulinemia; none of the 21 patients with other forms of hypogammaglobulinemia had reduced plasma gastrin secretion. A reduced integrated plasma gastrin re sponse but a normal incremental response to stimula tion with food was observed in only 1 of the 18 patients with the other forms of hypogammaglobulinemia. Among the patients with late-onset hypogammaglob ulinemia, 72 percent had an abnormally low gastrin response to bombesin, and 43 percent had a reduced response to food. Thus, the plasma gastrin response to bombesin distinguished late-onset hypogammaglobu linemia from the other forms, with a sensitivity of 72 percent and a specificity of 100 percent. This discrimi nation was better than that obtained with the foodstimulation test, which yielded a sensitivity of 43 per cent and a specificity of 94 percent. Since there was no correlation between a low plasma gastrin response and the age of the patient, or the duration of clinical symptoms, it is unlikely that such a response is merely a late manifestation of any type of hypogammaglobu linemia. Furthermore, gastrin responses were normal in the 10 patients with X-linked agammaglobuline mia, whose ages overlapped with those of patients with the late-onset form. Our findings may have clinical importance. The stimulation test may help in the classification of cases of primary hypogammaglobulinemia. Although var ious immunologic markers are available, such classi fication is difficult in certain patients.1'2'6 Also, the test may aid in the differentiation of primary hypogam maglobulinemia from hypogammaglobulinemia due to chronic lymphocytic leukemia and other lympho proliferative cancers. 11 We do not know whether, among patients with late-onset hypogammaglobuline mia, those with and without an abnormal gastrin response represent separate disease entities; this must be determined in large comparative studies. A test meal was given to 30 normal subjects, 14 patients with lateonset hypogammaglobulinemia, and 18 patients with other forms of hypogammaglobulinemia: 10 with X-linked agammaglobuline mia (crosses), 4 with early-onset hypogammaglobulinemia (cir cles), and 4 with secondary hypogammaglobulinemia (triangles). pM-120min denotes picomoles per liter per 120 minutes.
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THE NEW ENGLAND JOURNAL OF MEDICINE June 16, 1988 We observed no obvious clinical or biochemical dif ferences between the two groups. The test may also provide a noninvasive way to identify patients with hypogammaglobulinemia who are at risk for gastric cancer. It has been shown that among patients with late-onset hypogammaglobuline mia, there is a 50-fold increase in the incidence of gastric cancer2/; such an elevation has not been ob served among patients with other types of hypogam maglobulinemia. In fact, patients with late-onset hy pogammaglobulinemia have the highest known risk of gastric cancer. Therefore, a low plasma gastrin re sponse to bombesin or food may serve as a marker in the selection of patients for prospective gastroscopic evaluation. Since a low plasma gastrin response to bombesin has been found in patients with gastric can cer but normal serum gammaglobulin levels,28 it is tempting to hypothesize that the development of gas tric cancer is restricted to patients with abnormal gas trin secretion. Prospective studies are needed to sup port or reject this hypothesis, however.
The mechanism of the low plasma gastrin response to bombesin and food is unknown. Bombesin, a neuro peptide, is involved in the vagal stimulation of gastrin release from the gastric antrum.'2 The infusion of bombesin is a potent stimulus of gastrin secretion in several species of animals and in humans.30,31,33 Un like food, which stimulates gastrin release from both the antrum and the duodenum, bombesin mainly J stimulates the antral G cells.31 The normal postpran dial secretion of plasma gastrin in some patients with late-onset hypogammaglobulinemia, despite a re duced response to bombesin, may be caused by release of gastrin from the duodenum after stimulation with food. It is not known whether the abnormally low gas trin response is due to a reduced sensitivity of antral G cells to stimulation with bombesin or food, or a reduc tion in the number of G cells. It should be noted that none of our patients had abnormal gastric symptoms. Low basal plasma concentrations of gastrin have pre viously been reported in patients with pernicious anemia associated with hypogammaglobulinemia,18 whereas elevated gastrin levels are usually observed in patients with pernicious anemia who have normal concentrations of serum gammaglobulin.35,30 In the present study, abnormally low plasma gastrin secre tion was not restricted to patients with pernicious ane mia (3 of the 18 patients studied).
We have shown that, in contrast to patients with other types of hypogammaglobulinemia, the majority of patients with late-onset hypogammaglobulinemia have a reduced plasma gastrin response to food or bombesin. Plasma gastrin secretion can therefore be used as a marker of this type of immunodeficiency. Since bombesin is not readily available, stimulation with food may be the preferred initial diagnostic pro cedure, although the sensitivity of the test of post prandial gastrin secretion is somewhat lower than that of the test using bombesin. Both tests indicate hetero geneity among patients with late-onset hypogamma globulinemia and may help to identify those with an increased risk of gastric cancer. Kaplan-Meier analysis of both relapse-free and overall survival times showed that the presence of a near-diploid tumor stem line was associated with improved outcome (P = 0.003 for each comparison). After a median followup time of three years, pulmonary metastases developed in only 2 patients in the group with near-diploid lines, in contrast to 7 of the 10 with hyperdiploid lines exclu sively. Near diploidy remained significantly associated with improved relapse-free survival after adjustment for the influence of age, the only clinical variable that showed prognostic strength in this analysis (P<0.01; rel ative risk, 0.08; 95 percent confidence interval, 0.02 to 0.48).
Our findings demonstrate the usefulness of flow-cytometric determination of tumor-cell ploidy for predicting the sensitivity of histologically high-grade osteosarcoma to chemotherapeutic agents. Patients with a near-diploid tumor stem line can be expected to respond favorably to adjuvant chemotherapy as used in this study, where as those with only hyperdiploid lines should be consid ered as candidates for alternative therapy. been the lack of understanding of the biologic factors that determine the sensitivity of a particular tumor to drugs.13 As a first step toward identifying clinically useful prognostic markers in this disease, we measured the DNA content of tumor cells collected before treat ment in patients who had been enrolled in the multiinstitutional study of Link et al.1 This approach was attractive because measurement of cellular DNA con tent according to flow-cytometric techniques provides reliable estimates of the chromosome number (ploidy) in malignant stem lines and correlates well with the response to chemotherapy in childhood acute lympho blastic leukemia,14 neuroblastoma of infants,15 and Wilms' tumor.10 Hiddemann et al.1' have shown that measurement of DNA in patients with osteosarcoma can distinguish between hyperdiploid tumors with highly malignant features and tumors classified as parosteal variants, which have diploid DNA stem lines, well-differentiated histologic features, and a rel atively favorable prognosis.
The results of our investigation indicate that histo logically high-grade osteosarcomas with near-diploid stem lines respond significantly better to adjuvant combination chemotherapy than do tumors with only hyperdiploid lines. Patients whose tumors do not have
